Side-by-side financials for APRE and ABBV. Every figure below comes from audited SEC filings and refreshed market data.
| Metric | APRE | ABBV |
|---|---|---|
| Market cap | - | $400.96 B |
| US-listed rank | - | #31 |
| Revenue (latest FY) | - | $61.16B |
| Net income (latest FY) | -$12.60M | $4.23B |
| Net margin | - | 6.9% |
| P/E (trailing FY) | - | 94.9 |
| SEC filings | 425 | 1,008 |
Full pages: Aprea Therapeutics, Inc. and AbbVie Inc., or browse the full rankings.